MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

Search

Recursion Pharmaceuticals Inc

Închisă

SectorSănătate

5.57 4.11

Rezumat

Modificarea prețului

24h

Curent

Minim

5.35

Maxim

5.76

Indicatori cheie

By Trading Economics

Venit

-24M

-202M

Vânzări

10M

15M

Marjă de profit

-1,373.259

Angajați

800

EBITDA

-26M

-191M

Recomandări

By TipRanks

Recomandări

Neutru

Prognoză pe 12 luni

+11.94% upside

Dividende

By Dow Jones

Următoarele câștiguri

7 aug. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-313M

2B

Deschiderea anterioară

1.46

Închiderea anterioară

5.57

Sentimentul știrilor

By Acuity

60%

40%

328 / 376 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

Recursion Pharmaceuticals Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

9 iul. 2025, 15:46 UTC

Principalele dinamici ale pieței

BitMine Shares Fall After Closing of $250 Million Private Placement

9 iul. 2025, 23:44 UTC

Market Talk

Gold Edges Higher Amid U.S. Tariff Concerns -- Market Talk

9 iul. 2025, 23:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

9 iul. 2025, 23:42 UTC

Market Talk

Nikkei May Trade Rangebound as U.S. Tariff Uncertainty Continues -- Market Talk

9 iul. 2025, 22:59 UTC

Market Talk

Reliance Worldwide's Costs at Risk From Copper Tariffs -- Market Talk

9 iul. 2025, 22:59 UTC

Market Talk

Global Equities Roundup: Market Talk

9 iul. 2025, 20:50 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Health Care Roundup: Market Talk

9 iul. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

9 iul. 2025, 20:26 UTC

Câștiguri

Nvidia Is the Most Valuable Company Ever. Why $5 Trillion Could Be Next. -- Barrons.com

9 iul. 2025, 19:18 UTC

Market Talk

Oil Futures End Little Changed After Big U.S. Crude Stock Build -- Market Talk

9 iul. 2025, 19:03 UTC

Market Talk

U.S. Natural Gas Posts Back-to-Back Losses -- Market Talk

9 iul. 2025, 18:31 UTC

Market Talk

Some Fed Officials Supported Considering July Cut -- Market Talk

9 iul. 2025, 17:07 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Honeywell's Streamlining Efforts Clear Path for Stock to Catch Up -- Market Talk

9 iul. 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk -2-

9 iul. 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

9 iul. 2025, 16:20 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Health Care Roundup: Market Talk

9 iul. 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

9 iul. 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

9 iul. 2025, 16:14 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

9 iul. 2025, 16:14 UTC

Market Talk

Rents in Canada Soften For Ninth-Straight Month -- Market Talk

9 iul. 2025, 16:14 UTC

Achiziții, Fuziuni, Preluări

Apple Has Dropped the Ball on AI. Buying Perplexity Could Help It Catch Up, Say Analysts. -- Barrons.com

9 iul. 2025, 16:12 UTC

Market Talk

Gold Futures Broadly Flat in Largely Directionless Trade -- Market Talk

9 iul. 2025, 16:08 UTC

Market Talk

Oil Ticks Higher Amid Large U.S. Crude Build, Red Sea Tensions, Tariff Uncertainty -- Market Talk

9 iul. 2025, 15:31 UTC

Principalele dinamici ale pieței

BitMine Shares Fall After Closing of $250M Private Placement

9 iul. 2025, 15:31 UTC

Market Talk
Achiziții, Fuziuni, Preluări

With Competing Bids Unlikely, Merck's Path to Acquiring Verona Looks Smooth -- Market Talk

9 iul. 2025, 15:27 UTC

Market Talk

Copper Rally Expected to Fade Amid Tepid Global Demand -- Market Talk

9 iul. 2025, 14:36 UTC

Achiziții, Fuziuni, Preluări

Merck to Buy Verona Pharma in $10 Billion Deal -- 2nd Update

9 iul. 2025, 14:31 UTC

Achiziții, Fuziuni, Preluări

Meta Has Surged on the Back of AI Software. Why Hardware Is the Next Play. -- Barrons.com

9 iul. 2025, 14:26 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

9 iul. 2025, 14:26 UTC

Market Talk

Aug 1 Tariffs Will Boost Average Rate Near 15%, JPMorgan Estimates -- Market Talk

Comparație

Modificare preț

Recursion Pharmaceuticals Inc Așteptări

Obiectiv de preț

By TipRanks

11.94% sus

Prognoză pe 12 luni

Medie 6 USD  11.94%

Maxim 8 USD

Minim 4 USD

În baza a 6 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruRecursion Pharmaceuticals Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

6 ratings

1

Cumpărare

5

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

4.15 / 4.75Suport & Rezistență

Termen scurt

Very Strong Bearish Evidence

Termen mediu

Bearish Evidence

Termen lung

Bearish Evidence

Sentiment

By Acuity

328 / 376 Clasament în Sănătate

Sentimentul știrilor

Evidențe de scădere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.